Organisation paid for research Program year 2025 Source: CMS Open Payments

Manuel Montero

Neither a doctor nor a teaching hospital

Research payments

$4,213,769

47 payments

Through program year 2025, Manuel Montero is reported as receiving $4,213,769 in research payments, across 47 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$1,482,936	16
2024	Research	$1,747,999	15
2023	Research	$925,936	10
2022	Research	$36,724	2
2021	Research	$20,175	4

Breakdown

Who paid Research payments · program years 2021–2025

AstraZeneca Pharmaceuticals LP $4,150,075 44 payments
AstraZeneca UK Limited $63,695 3 payments

Studies the money was for Research payments · program years 2021–2025

A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $1,581,626 8 payments
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions $1,185,035 9 payments
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $778,762 6 payments
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure $301,147 4 payments
A Randomised Double-Blind Placebo-Controlled Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension $176,855 8 payments
A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease $79,478 3 payments
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure with Left Ventricular Ejection Fraction (LVEF) Below 55 percent and Chronic Kidney Disease $47,228 1 payment
NEUTRALIZE - Lokelma Metabolic Acidosis Study A double-blind randomized placebo-controlled parallel design multicenter phase IIIb study of Lokelmas effect on serum potassium and serum bicarbonate in patients with CKD hyperkalemia and metabolic acidosis of CKD $47,173 6 payments
A Phase II Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer ORION $16,467 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.